explore -WSS

explore

author：Wikipedia 2025-09-01 15:16:04 - browse：2

David Liu and Jonathan Wosen on the STAT Summit stage. — David Liu (left) with reporter Jonathan Wosen at the 2022 STAT Summit. STAT

David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching a company focused on delivering gene-editing machinery to precise cells and tissues in the body, STAT has learned.

The company, known as Nvelop, already raised a $100 million seed round last year, according to PitchBook. It is being run by Jeff Walsh, a former top executive at Bluebird Bio, and it recently recruited Bluebird’s head of research, Melissa Bonner, according to two people with knowledge of the situation. Bluebird had not previously disclosed Bonner’s departure.

Nvelop is the latest entry in a race among top labs and deep-pocketed investors to solve a delivery problem that has stunted efforts to turn CRISPR and other genetic tools into disease-altering medicines. The goal is to develop a cargo system precise enough to deliver CRISPR or other machinery to cells of a researchers’ choosing, particularly tissues that have been hard to reach with previous approaches, like neurons, muscle, and blood stem cells.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Overprescribed: High cost isn't America's only drug problem

WSS

Hundreds died while taking an arthritis drug, but nobody alerted patients

Scientific mystery highlights the blind spots in genomics databases

The science behind Janet Jackson's pregnancy at 49

The story of mRNA: From a loose idea to a tool that may help curb Covid

Covid silver lining: Unprecedented look at human immune system

U.K. decision on ALS drug has neurologists, advocates up in arms

entertainment

explore

focus

Novavax promises a turnaround & Lilly roils the obesity market

Donald Trump's relentless attacks on special counsel Jack Smith

Jerome Adams on the need for new antivirals for Covid

Medicare Advantage 2025 payments will dip, Biden administration says

Anesthesiologist group: stop taking Ozempic before surgery

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Sports medicine is finally prioritizing gender equality

Why drug prescriptions should include diagnoses

hotspot

WATCH: Why do fingernails fall off when they're damaged?

Pancreatic cancer is often deadly, but new discoveries are raising hope

Paxlovid study fails to answer questions over benefit for broader groups

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

3 hurdles to bringing medical devices to the U.S. market

hotspot

hotspot

focus

knowledge